<DOC>
	<DOCNO>NCT01261936</DOCNO>
	<brief_summary>Menorrhagia term use define excessive menstrual blood loss , often base subjective judgment woman . Many arbitrary value , express milliliter blood , propose define symptom : 60 cycle also confirm preliminary study 87 healthy woman . The quantitative determination menstrual blood loss nevertheless rarely perform , research setting . Although menorrhagia quite frequent symptom healthy woman apparently haemostatically competent fertile age ( 20-30 % ) , incidence becomes high woman affect congenital coagulation factor deficiency ( 50-62.9 % ) inherit platelet defect , e.g . Glanzmann 's Thromboasthenia ( GT ) ; also von Willebrand Disease bleed symptom `` menorrhagia '' high prevalence ( 60-75 % ) ( 8 ) ; GT incidence 90 % report . This explain need study focus evaluation menorrhagia CBDs , address answer following , still unsolved question : 1 . Definition entity menstrual blood loss woman affect CBDs 2 . Elaboration specific treatment schedule type CBD 3 . Impact different specific treatment schedule kinetic entity menstrual loss ( treatment modify loss ? ) .</brief_summary>
	<brief_title>Evaluation Menses Congenital Bleeding Disorders</brief_title>
	<detailed_description>The following multicentric , observational , cross-over study intend apply easy simple system quantitative determination menstrual loss woman affect Congenital Bleeding Disorders ( CBDs ) . The evaluation menstrual loss represent scarcely studied field specific subset patient ( 1 ) , interest high incidence menorrhagia , changeable accord type CBDs , 60 100 % woman fertile age . The system adopt determination menstrual loss , call QUEM ( QUantitative Evaluation Menses ) , base collection tampon pad standard bag readily vacuum seal simple device whole woman 's period . QUEM already validate preliminary vitro ex vivo study ( 87 healthy woman woman CBDs ) , compare gold standard , Alkaline Haematin Method . A correlation coefficient close 1 obtain . In current study QUEM apply woman fertile age ( 18 e 45 year ) , ascertain diagnosis CBD ( FVII , FX , FII deficiency , Glanzmann von Willebrand disease , symptomatic Hemophilia A B carrier ) , follow heavy period reference hemophilia centre need specific treatment enrol multicentric study . Also woman apparently normal menses severe bleed disorder enrol . Women ascertain menorrhagia treat specific replacement therapy , already commonly adopt clinical practice base type CBD schedule reduce heavy period . The study evaluate 4 consecutive menstrual cycle , first second period without treatment ( possible ) follow two administration specific treatment . The bleeding anamnesis ( bleed score ) perform apply international reference method , already validate von Willebrand Disease type 1 ( vWD1 ) [ 2 ] adopt Italian multicentric study 814 patient affected different type VWD [ 3 ] . The determination score consider useful also CBDs . This study already approve IRC `` San Salvatore Hospital '' - L'Aquila-Italy . The study already enrol , Italy , woman . All needed material equipment provide ; patient carefully inform objective study follow short course illustrate use characteristic method propose ( QUEM ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<criteria>1 . Age 18 45 year ; 2 . Ascertained diagnosis one following inherit bleed disorder : 1 . Von Willebrand Disease type 1 , 2 , 3 severe moderate ( VWF : RCo &lt; 30 % ) , diagnose follow Italian guideline [ 4 ] 2 . Glanzmann Thromboasthenia 3 . Congenital Coagulation Factor VII , II X deficiency 4 . A B Haemophilia Carriers ( Factor VIII IX &lt; 25 % ) ; 3 . Bleeding Severity score &gt; 2 4 . Signing consent form . 1 . Under continuous antihemorrhagic prophylaxis 2 . Affected active cancer antiphospholipid antibodies syndrome 3 . History liver , kidney endocrine disorder 4 . Submucous uterine fibroid , uterine polyp malignancy 5 . Use oral contraceptive intrauterine device past three month 6 . Treatment nonsteroidal antiinflammatory drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Menorrhagia</keyword>
	<keyword>Congenital Bleeding Disorders ( CBDs )</keyword>
	<keyword>Diagnosis treatment menorrhagia CBDs</keyword>
</DOC>